The Latest Breaking News from Novo

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…

Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.

As surprise pregnancies multiply, some scientists are investigating whether weight loss drugs can improve fertility in women with polycystic ovary syndrome

Weight-loss drug kingpins Eli Lilly and Novo Nordisk could join the trillion-dollar company club before even Tesla, according to a report.

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Monday's global sell-off turned into a stock market rally attempt. Palantir, Eli Lilly and Fortinet were among the earnings winners.

As Congress pushes for Medicare to cover anti-obesity drugs, puzzlement remains about who should get them, for how long, and at what price.

Novo Nordisk stock tumbled Wednesday after the drugmaker reported a rare sales miss for its two biggest moneymakers, Ozempic and Wegovy.

Danish company, which also makes Ozempic, faces increasing competition from US rival Eli Lilly